Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

A cytokine signal inhibitor for rheumatoid arthritis enhances cancer metastasis via depletion of NK cells in an experimental lung metastasis mouse model of colon cancer.

Shimaoka H, Takeno S, Maki K, Sasaki T, Hasegawa S, Yamashita Y.

Oncol Lett. 2017 Sep;14(3):3019-3027. doi: 10.3892/ol.2017.6473. Epub 2017 Jun 23.

2.

Human Papillomavirus-Induced Cancer: Late Relapse in a Patient Treated With Tumor Necrosis Factor-Alpha Inhibitor.

Werberich GM, Strava T, Vizioli C, Fernandes GDS.

J Glob Oncol. 2016 Aug 24;3(3):275-277. doi: 10.1200/JGO.2016.005835. eCollection 2017 Jun. No abstract available.

3.

Casual or Causal? Two Unique Cases of Hodgkin's Lymphoma: A Case Report and Literature Review.

Malik F, Ali N, Jafri SIM, Fidler C.

Am J Case Rep. 2017 May 19;18:553-557. Review.

4.

Management of Inflammatory Bowel Disease in the Elderly Patient: Challenges and Opportunities.

Ananthakrishnan AN, Donaldson T, Lasch K, Yajnik V.

Inflamm Bowel Dis. 2017 Jun;23(6):882-893. doi: 10.1097/MIB.0000000000001099.

PMID:
28375885
5.

Reduced risk of all-cancer and solid cancer in Taiwanese patients with rheumatoid arthritis treated with etanercept, a TNF-α inhibitor.

Lan JL, Tseng CH, Chen JH, Cheng CF, Liang WM, Tsay GJ.

Medicine (Baltimore). 2017 Feb;96(7):e6055. doi: 10.1097/MD.0000000000006055.

6.

New and emerging therapies for the treatment of rheumatoid arthritis.

Feely MG.

Open Access Rheumatol. 2010 Jul 24;2:35-43. eCollection 2010. Review.

8.

Long-term use of adalimumab in the treatment of rheumatic diseases.

Papagoras C, Voulgari PV, Drosos AA.

Open Access Rheumatol. 2009 May 18;1:51-68. eCollection 2009. Review.

9.

Parents' information needs and influential factors when making decisions about TNF-α inhibitors.

Lipstein EA, Lovell DJ, Denson LA, Kim SC, Spencer C, Britto MT.

Pediatr Rheumatol Online J. 2016 Sep 15;14(1):53. doi: 10.1186/s12969-016-0113-5.

10.

Risk of lymphoma in patients exposed to antitumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.

Mercer LK, Galloway JB, Lunt M, Davies R, Low AL, Dixon WG, Watson KD; BSRBR Control Centre Consortium, Symmons DP, Hyrich KL.

Ann Rheum Dis. 2017 Mar;76(3):497-503. doi: 10.1136/annrheumdis-2016-209389. Epub 2016 Aug 8.

11.

Autoimmune/Inflammatory Arthritis Associated Lymphomas: Who Is at Risk?

Yadlapati S, Efthimiou P.

Biomed Res Int. 2016;2016:8631061. doi: 10.1155/2016/8631061. Epub 2016 Jun 27. Review.

12.

Oral non-Hodgkin's lymphoma in a patient with rheumatoid arthritis treated with etanercept and methotrexate.

Georgakopoulou EA, Achtari MD, Evangelou K, Kittas C.

J Clin Exp Dent. 2015 Feb 1;7(1):e180-2. doi: 10.4317/jced.51922. eCollection 2015 Feb.

13.

Pulmonary hodgkin lymphoma in a patient with Crohn's disease.

Park JY, Lee J.

Korean J Pathol. 2014 Oct;48(5):387-9. doi: 10.4132/KoreanJPathol.2014.48.5.387. Epub 2014 Oct 27. No abstract available.

14.

The risk of cancer in patients with rheumatoid arthritis taking tumor necrosis factor antagonists: a nationwide cohort study.

Wu CY, Chen DY, Shen JL, Ho HJ, Chen CC, Kuo KN, Liu HN, Chang YT, Chen YJ.

Arthritis Res Ther. 2014 Sep 30;16(5):449. doi: 10.1186/s13075-014-0449-5. Erratum in: Arthritis Res Ther. 2016;18(1):110.

15.

Treating inflammatory bowel disease by adsorptive leucocytapheresis: a desire to treat without drugs.

Saniabadi AR, Tanaka T, Ohmori T, Sawada K, Yamamoto T, Hanai H.

World J Gastroenterol. 2014 Aug 7;20(29):9699-715. doi: 10.3748/wjg.v20.i29.9699. Review.

16.

TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: a case report and literature review.

Ben Musa R, Usha L, Hibbeln J, Mutlu EA.

World J Gastroenterol. 2014 May 21;20(19):5912-7. doi: 10.3748/wjg.v20.i19.5912. Review.

17.

Acute promyelocytic leukaemia (APL) in a patient with Crohn's disease and exposure to infliximab: a rare clinical presentation and review of the literature.

Mohammad F, Vivekanandarajah A, Haddad H, Shutty CM, Hurford MT, Dai Q.

BMJ Case Rep. 2014 May 19;2014. pii: bcr2013203318. doi: 10.1136/bcr-2013-203318. Review.

18.

Small molecule inhibitor of antigen binding and presentation by HLA-DR2b as a therapeutic strategy for the treatment of multiple sclerosis.

Ji N, Somanaboeina A, Dixit A, Kawamura K, Hayward NJ, Self C, Olson GL, Forsthuber TG.

J Immunol. 2013 Nov 15;191(10):5074-84. doi: 10.4049/jimmunol.1300407. Epub 2013 Oct 11.

19.

Cancer risk in immune-mediated inflammatory diseases (IMID).

Beyaert R, Beaugerie L, Van Assche G, Brochez L, Renauld JC, Viguier M, Cocquyt V, Jerusalem G, Machiels JP, Prenen H, Masson P, Louis E, De Keyser F.

Mol Cancer. 2013 Aug 29;12(1):98. doi: 10.1186/1476-4598-12-98. Review.

20.

Supplemental Content

Support Center